Odapipam (INNTooltip International Nonproprietary Name; developmental code names NNC 01-0756, NNC-756, NO-756) is a selective D1 receptor antagonist of the benzazepine group which was investigated as a potential antipsychotic but was never marketed. It has more than 5,000-fold selectivity for the dopamine D1 receptor (Ki = 0.17 nM) over the dopamine D2 receptor (Ki = 942 nM). Its affinities for other dopamine receptors, such as the dopamine D5 receptor, were not reported. In addition to the dopamine D1 receptor, odapipam showed relatively high affinity for the serotonin 5-HT2 receptor (Ki = 4.5 nM; 26-fold lower than for the D1 receptor). The drug was first described in the scientific literature by 1988.
See also Substituted 3-benzazepine List of investigational antipsychotics Berupipam (NNC 22-0010) Ecopipam (SCH-39166) NNC 01-0687 (ADX-10061) SCH-23390
References


